BSD Medical’s System Featured at Symposium on Hyperthermia for the Treatment of Cancer in Turkey

  BSD Medical’s System Featured at Symposium on Hyperthermia for the Treatment
  of Cancer in Turkey

Business Wire

SALT LAKE CITY -- November 21, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
today announced that the Company's BSD-2000-3D/MR System was featured at a
symposium focused on the use of hyperthermia in the treatment of cancer held
in Ankara, Turkey. The symposium, "MR Kontrollü Derin Bölgesel Hipertermi (MR
controlled deep regional hyperthermia)," was hosted by Meyra Saglik, BSD’s
distributor in Turkey, and chaired by Professor Dr. M. Kadri Altundag, MD,
PhD, head of medical oncology department of Hacettepe University in Ankara.

Among the participants were senior officers of the Turkish Ministry of Health
as well as key opinion leaders in the field of oncology in Turkey. The
symposium was opened by a presentation from Professor Dr. Murat Gültekin, MD,
Director of the Cancer Control Department at the Turkish Ministry of Health.
His talk was followed by presentations from Dr. Jacoba van der Zee, MD, PhD,
Erasmus University Medical Center, Rotterdam, The Netherlands, and Assistant
Professor Dr. Lars Lindner, MD, PhD, University of Munich Medical Center,
Munich, Germany.

“We were very proud to host a successful symposium that included presentations
from many prestigious speakers,” said Akif Unzuncarsili, CEO of Meyra Saglik.
“We are looking forward to the first installation of a BSD hyperthermia system
in Turkey.”

Turkey has a population of 80 million and is a strong market for medical
device companies. The Turkish Ministry of Health has set up a program for
improving the treatment of cancer in Turkey that includes investment in new
technology.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.